No Data
No Data
Sisram Med [01696] is now trading at HKD 3.53, with a rise of 10.66%.
As of 09:35, Sisram Med [01696] reported a price of HKD 3.53, up HKD 0.34 or 10.66% from the previous closing price of HKD 3.19. The trading volume was 0.6276 million HKD. The highest price today was HKD 3.53, and the lowest price was HKD 3.31. Based on the previous closing price, the 10-day average price was HKD 4.19, and the 50-day average price was HKD 3.76. The PE ratio is currently 7.41 times, and the 14-day strength index is 48.10.
Express News | Sirsram Medical Announces Nmpa Approval for Daxxify
Sirsram Medical Announces NMPA Approval for DAXXIFY
Sisram Med: The world's first patented long-acting type A botulinum toxin Daxifei has officially obtained approval for listing in China.
Hong Kong, September 9, 2024 / PRNewswire / - Sisram Medical Technology Co., Ltd. (referred to as "Sisram" in English, stock code: 1696.HK), together with its subsidiaries collectively referred to as "the Group", announced today that its trademarked revolutionary long-acting type A botulinum toxin product under the brand name Daxify (in English, DAXXIFY) (project code RT002) has officially obtained approval from the National Medical Products Administration of China for its registration application. This product is used for temporary improvement in adults.
Sisram Med (01696.HK): Injection type A botulinum toxin product Daxifei approved in China.
On September 9, Sisram Medical Technology (01696.HK) announced that it has been authorized by Fosun Pharma Industry Development Co., Ltd. in Shanghai (hereinafter referred to as "Fosun Pharma Industry") to market the injectable type A botulinum toxin, DaxibotulinumtoxinA-lanm (operating under the Chinese trademark Daxif). The drug, with the English trademark DAXXIFY and project code RT002, is used for the temporary improvement of moderate to severe glabellar lines caused by the activity of the corrugator and/or procerus muscles in adults. The pharmaceutical registration application for this product has recently been approved by the National Medical Products Administration.
sisram med (01696.HK) granted a total of 1.32 million restricted share units.
On September 4th, Groong Herald announced that on September 4, 2024, under the 2021 Restricted Share Unit Program, a total of 1.32 million restricted share units were granted to a total of 59 participants. The purpose of this grant is to effectively attract and retain core talents who have a significant impact and contribution to the company's business growth, inspire the entrepreneurial passion of core employees, and help the company achieve healthy and long-term development, which is also in line with the overall interests of the company and shareholders. The recipients of this grant are all new grantees, meaning they did not receive restricted share units under the 2021 Restricted Share Unit Program.
No Data